Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

Financials ($)
Sales 2016 66,9 M
EBIT 2016 4,47 M
Net income 2016 -9,49 M
Debt 2016 48,8 M
Yield 2016 -
Sales 2017 91,2 M
EBIT 2017 10,9 M
Net income 2017 -2,55 M
Debt 2017 72,1 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 6,51x
EV / Sales2017 5,03x
Capitalization 387 M
More Financials
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
03/07Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
11/30 TELIGENT, INC. : Announces FDA Approval Of Clobetasol Propionate Lotion 0.05%
11/16 TELIGENT : Ranked 200 Fastest Growing Company in North America on Deloitte's 201..
11/16 TELIGENT, INC. : Ranked 200 Fastest Growing Company in North America on Deloitte..
11/16 TELIGENT, INC. : To Present At 7th Annual Craig-Hallum Alpha Select Conference O..
11/08 TELIGENT : Management's Discussion and Analysis of Financial Condition and Resul..
10/28 TELIGENT : reports 3Q loss
10/27 TELIGENT, INC. : Results of Operations and Financial Condition, Financial Statem..
10/27 TELIGENT, INC. : Announces Third Quarter 2016 Results
10/14 TELIGENT, INC. : To Hold Conference Call For 3rd Quarter 2016 Results
10/11 TELIGENT : Announces The Opening Of A Product Development Laboratory In Estonia
More news
Sector news : Pharmaceuticals - NEC
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal -- Update
12/07DJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal
12/07DJMARKET SNAPSHOT : Dow, S&P 500 Set Intraday Records, But Health-care Slumps On T..
More sector news : Pharmaceuticals - NEC
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 9,75 $
Spread / Average Target 34%
Consensus details
EPS Revisions
More Estimates Revisions
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Sanjay Samudre Operations Director
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.09%304 863
PFIZER INC.-2.23%191 517
ROCHE HOLDING LTD.-19.65%190 397
NOVARTIS AG-20.79%180 387
MERCK & CO., INC.14.12%166 200
More Results